VIIV Company Profile
✉ Email this page to a colleague
What is the competitive landscape for VIIV, and when can generic versions of VIIV drugs launch?
VIIV has twenty-six approved drugs.
There are twelve US patents protecting VIIV drugs.
There are five hundred and fifteen patent family members on VIIV drugs in fifty-nine countries and two hundred and eleven supplementary protection certificates in eighteen countries.
Summary for VIIV
International Patents: | 515 |
US Patents: | 12 |
Tradenames: | 19 |
Ingredients: | 17 |
NDAs: | 26 |
Patent Litigation for VIIV: | See patent lawsuits for VIIV |
PTAB Cases with VIIV as patent owner: | See PTAB cases with VIIV as patent owner |
Drugs and US Patents for VIIV
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Viiv Hlthcare | TIVICAY | dolutegravir sodium | TABLET;ORAL | 204790-002 | Jun 9, 2016 | DISCN | Yes | No | 8,129,385*PED | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Viiv Hlthcare | APRETUDE | cabotegravir | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 215499-001 | Dec 20, 2021 | RX | Yes | Yes | 11,224,597 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Viiv Hlthcare | VOCABRIA | cabotegravir sodium | TABLET;ORAL | 212887-001 | Jan 21, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VIIV
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Viiv Hlthcare | CABENUVA KIT | cabotegravir; rilpivirine | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 212888-001 | Jan 21, 2021 | 6,838,464 | ⤷ Sign Up |
Viiv Hlthcare | COMBIVIR | lamivudine; zidovudine | TABLET;ORAL | 020857-001 | Sep 26, 1997 | 5,905,082*PED | ⤷ Sign Up |
Viiv Hlthcare | TRIZIVIR | abacavir sulfate; lamivudine; zidovudine | TABLET;ORAL | 021205-001 | Nov 14, 2000 | 4,828,838 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for VIIV drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Oral Solution | 10 mg/mL | ➤ Subscribe | 2011-11-22 |
➤ Subscribe | Tablets | 300 mg | ➤ Subscribe | 2009-01-28 |
➤ Subscribe | Tablets | 700 mg | ➤ Subscribe | 2012-01-18 |
➤ Subscribe | Tablets | 600 mg/300 mg | ➤ Subscribe | 2007-09-27 |
➤ Subscribe | Tablets | 600 mg/50 mg/300 mg | ➤ Subscribe | 2017-08-14 |
➤ Subscribe | Tablets | 150 mg and 300 mg | ➤ Subscribe | 2007-10-16 |
➤ Subscribe | Tablets | 150 mg and 300 mg | ➤ Subscribe | 2011-08-08 |
➤ Subscribe | Oral Solution | 20 mg/ml | ➤ Subscribe | 2012-12-27 |
➤ Subscribe | Tablets | 150 mg/300 mg | ➤ Subscribe | 2007-06-26 |
➤ Subscribe | Tablets | 10 mg, 25 mg and 50 mg | ➤ Subscribe | 2017-08-14 |
➤ Subscribe | Tablets | 300 mg/150 mg/300 mg | ➤ Subscribe | 2011-03-22 |
International Patents for VIIV Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Russian Federation | 2011121785 | ⤷ Sign Up |
Japan | 2009541271 | ⤷ Sign Up |
Hungary | S1600058 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for VIIV Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1632232 | SPC/GB17/007 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: A COMBINATION OF RILPIVIRINE HYDROCHLORIDE AND TENOFOVIR ALAFENAMIDE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR TENOFOVIR ALAFENAMIDE FUMARATE; REGISTERED: UK EU/1/16/1112 (NI) 20160623; UK PLGB 11972/0019 20160623 |
1874117 | 14C0041 | France | ⤷ Sign Up | PRODUCT NAME: DOLUTEGRAVIR ET SES SELS OU SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES,NOTAMMENT LE DOLUTEGRAVIR SODIQUE.; REGISTRATION NO/DATE: EU/1/13/892/001-002 20140121 |
2932970 | 122018000125 | Germany | ⤷ Sign Up | PRODUCT NAME: EINE KOMBINATION UMFASSEND DOLUTEGRAVIR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON (Z. B DOLUTEGRAVIR NATRIUM) UND RILPIVIRIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON (Z.B RILPIVIRIN HYDROCHLORID); REGISTRATION NO/DATE: EU/1/18/1282 20180516 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.